Search

Your search keyword '"Iain Squire"' showing total 8 results
Start Over Author "Iain Squire" Topic business.industry
8 results on '"Iain Squire"'

1. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction

Author

Domingo Pascual-Figal, Rolf Wachter, Michele Senni, Weibin Bao, Adele Noè, Heike Schwende, Dmytro Butylin, Margaret F. Prescott, Jacek Gniot, Maria Mozheiko, Malgorzata Lelonek, Antonio Reyes Dominguez, Thomas Horacek, Enrique Garcia del Rio, Zhanna Kobalava, Christian Eugen Mueller, Yuksel Cavusoglu, Ewa Straburzynska-Migaj, Miroslav Slanina, Juergen vom Dahl, Alisdair Ryding, Andrew Moriarty, Manuel Beltran Robles, Julio Nunez Villota, Antonio Garcia Quintana, Thorsten Nitschke, Jose Manuel Garcia Pinilla, Luis Almenar Bonet, Said Chaaban, Samia Filali zaatari, Jindrich Spinar, Wlodzimierz Musial, Khaled Abdelbaki, Jan Belohlavek, Wolfgang Fehske, Michael Carlos Bott, Geir Hoegalmen, Marisa Crespo Leiro, Ismail Turkay Ozcan, Wilfried Mullens, Radim Kryza, Riadh Al-Ani, Krystyna Loboz-Grudzien, Lyudmila Ermoshkina, Silvia Hojerova, Alberto Alfredo Fernandez, Lenka Spinarova, Harald Lapp, Efraim Bulut, Filipa Almeida, Alexander Vishnevsky, Margita Belicova, Domingo Pascual, Klaus Witte, Kenneth Wong, Walter Droogne, Marc Delforge, Martin Peterka, Hans-Georg Olbrich, Stefano Carugo, Jadwiga Nessler, Thao Huynh McGill, Burkhard Huegl, Ibrahim Akin, Ilidio Moreira, Andrey Baglikov, Jeetendra Thambyrajah, Chris Hayes, Marcelo Raul Barrionuevo, Zerrin Yigit, Hakki Kaya, Zdenek Klimsa, Martin Radvan, Christoph Kadel, Ulf Landmesser, Giuseppe Di Tano, Malgorzata Buksinska Lisik, Candida Fonseca, Luis Oliveira, Irene Marques, Luis Miguel Santos, Egon Lenner, Peter Letavay, Manuel Gomez Bueno, Paula Mota, Aaron Wong, Kristian Bailey, Paul Foley, Eduardo Hasbani, Sean Virani, Tony Abdel Massih, Shukri Al-Saif, Milos Taborsky, Marta Kaislerova, Zuzana Motovska, Aron Ariel Cohen, Damien Logeart, Dierk Endemann, Daniel Ferreira, Dulce Brito, Peter Kycina, Entela Bollano, Enrique Galve Basilio, Lorenzo Facila Rubio, Marcos Garcia Aguado, Lilia Beatriz Schiavi, Daniel Francisco Zivano, Eva Lonn, Ali El Sayed, Anne-Catherine Pouleur, Alex Heyse, Alexandr Schee, Rostislav Polasek, Marek Houra, Christophe Tribouilloy, Marie France Seronde, Michel Galinier, Michel Noutsias, Peter Schwimmbeck, Ingo Voigt, Dirk Westermann, Giovanni Pulignano, Johnny Vegsundvaag, Jose Alexandre Da Silva Antunes, Pedro Monteiro, Jan Stevlik, Eva Goncalvesova, Beata Hulkoova, Antonio Juan Castro Fernandez, Ceri Davies, Iain Squire, Philippe Meyer, Richard Sheppard, Tayfun Sahin, Karel Sochor, Guillaume De Geeter, Alexander Schmeisser, Joachim Weil, Ana Oliveira Soares, Olga Bulashova Vasilevna, Andrey Oshurkov, Shahid Junejo Sunderland, Jason Glover, Tomas Exequiel, Eric Decoulx, Sven Meyer, Thomas Muenzel, Fernando Frioes, Georgy Arbolishvili, Anna Tokarcikova, Patric Karlstrom, Joan Carles Trullas Vila, Gonzalo Pena Perez, Rajiv Sankaranarayanan, Thuraia Nageh, Diego Cristian Alasia, Marwan Refaat, Burcu Demirkan, Jehad Al-Buraiki, and Shadi Karabsheh

Subjects
medicine.medical_specialty, Ejection fraction, Acute decompensated heart failure, business.industry, medicine.drug_class, 030204 cardiovascular system & hematology, medicine.disease, Sacubitril, 03 medical and health sciences, 0302 clinical medicine, Valsartan, Heart failure, Internal medicine, Natriuretic peptide, Cardiology, Medicine, Decompensation, cardiovascular diseases, 030212 general & internal medicine, Cardiology and Cardiovascular Medicine, business, hormones, hormone substitutes, and hormone antagonists, Sacubitril, Valsartan, medicine.drug
Abstract

Objectives This study examined the effects of sacubitril/valsartan on N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels and determined patient characteristics associated with favorable NT-proBNP reduction response. Background NT-proBNP levels reflect cardiac wall stress and predict event risk in patients with acute decompensated heart failure (ADHF). Methods Post-hoc analysis of the TRANSITION (Comparison of Pre- and Post-discharge Initiation of Sacubitril/Valsartan Therapy in HFrEF Patients After an Acute Decompensation Event) study, including stabilized ADHF patients with reduced ejection fraction, randomized to open-label sacubitril/valsartan initiation in-hospital (pre-discharge) versus post-discharge. NT-proBNP was measured at randomization (baseline), discharge, and 4 and 10 weeks post-randomization. A favorable NT-proBNP response was defined as reduction to ≤1,000 pg/ml or >30% from baseline. Results In patients receiving sacubitril/valsartan in-hospital, NT-proBNP was reduced by 28% at discharge, with 46% of patients obtaining favorable NT-proBNP reduction response compared with a 4% reduction and 18% favorable response rate in patients initiated post-discharge (p Conclusions In-hospital initiation of sacubitril/valsartan produced rapid reductions in NT-proBNP, statistically significant at discharge. A favorable NT-proBNP response over time was associated with a better prognosis and predicted by higher starting dose and predisposing clinical profile. (Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event [TRANSITION]; NCT02661217)

Published
2020

2. Inter-study repeatability of circumferential strain and diastolic strain rate by CMR tagging, feature tracking and tissue tracking in ST-segment elevation myocardial infarction

Author

Sheraz A Nazir, Anvesha Singh, Iain Squire, Jayanth R. Arnold, Jamal N Khan, Abhishek Shetye, and Gerry P McCann

Subjects
Male, Tissue tracking, Systole, Diastole, 030204 cardiovascular system & hematology, 030218 nuclear medicine & medical imaging, STEMI, 03 medical and health sciences, 0302 clinical medicine, Tagging, Predictive Value of Tests, medicine, Humans, ST segment, Radiology, Nuclear Medicine and imaging, Repeatability, Myocardial infarction, Cardiac imaging, Original Paper, business.industry, Reproducibility of Results, Heart, Middle Aged, Strain rate, medicine.disease, Magnetic Resonance Imaging, Feature tracking, ST Elevation Myocardial Infarction, Female, Cardiology and Cardiovascular Medicine, Nuclear medicine, business
Abstract

Strain assessment allows accurate evaluation of myocardial function and mechanics in ST-segment elevation myocardial infarction (STEMI). Strain using cardiovascular magnetic resonance (CMR) has traditionally been assessed with tagging but limitations of this technique have led to more widespread use of alternative methods, which may be more robust. We compared the inter-study repeatability of circumferential global peak-systolic strain (Ecc) and peak-early diastolic strain rate (PEDSR) derived by tagging with values obtained using novel cine-based software: Feature Tracking (FT) (TomTec, Germany) and Tissue Tracking (TT) (Circle cvi42, Canada) in patients following STEMI. Twenty male patients (mean age 56 ± 10 years, mean infarct size 13.7 ± 7.1% of left ventricular mass) were randomised to undergo CMR 1–5 days post-STEMI at 1.5 T or 3.0 T, repeated after ten minutes at the same field strength. Ecc and PEDSR were assessed using tagging, FT and TT. Inter-study repeatability was evaluated using Bland–Altman analyses, coefficients of variation (CoV) and intra-class correlation coefficient (ICC). Ecc (%) was significantly lower with tagging than with FT or TT at 1.5 T (− 9.5 ± 3.3 vs. − 17.5 ± 3.8 vs. −15.5 ± 5.2, respectively, p −1): 1.5 T (0.6 ± 0.2 vs. 1.5 ± 0.4 vs. 1.0 ± 0.4, for tagging, FT and TT respectively, p Ecc at 1.5 T was good for tagging and excellent for FT and TT: CoV 16.7%, 6.38%, and 8.65%, respectively. Repeatability for Ecc at 3.0 T was good for all three techniques: CoV 14.4%, 11.2%, and 13.0%, respectively. However, repeatability of PEDSR was generally lower than that for Ecc at 1.5 T (CoV 15.1%, 13.1%, and 34.0% for tagging, FT and TT, respectively) and 3.0 T (CoV 23.0%, 18.6%, and 26.2%, respectively). Following STEMI, Ecc and PEDSR are higher when measured with FT and TT than with tagging. Inter-study repeatability of Ecc is good for tagging, excellent for FT and TT at 1.5 T, and good for all three methods at 3.0 T. The repeatability of PEDSR is good to moderate at 1.5 T and moderate at 3.0 T. Cine-based methods to assess Ecc following STEMI may be preferable to tagging.

Published
2020

3. Empagliflozin in heart failure with a preserved ejection fraction

Author

Bela Merkely, Nikolaus Marx, Subodh Verma, Michele Senni, Eduardo Chuquiure-Valenzuela, James L. Januzzi, Vijay K. Chopra, Dong-Ju Choi, Stefan D. Anker, Stefano Taddei, Ileana L. Piña, Juan Esteban Gomez-Mesa, Jose R Gonzalez-Juanatey, Dragos Vinereanu, Sergio V. Perrone, Faiez Zannad, Jian Zhang, Carolyn Su Ping Lam, Stuart J. Pocock, Stefan Janssens, Iain Squire, Waheed Jamal, Hans-Peter Brunner-La Rocca, Peter E. Carson, Javed Butler, David K.L. Sim, EMPEROR-Preserved Trial Investigators, Stephen J. Nicholls, Hiroyuki Tsutsui, Janet Schnee, Martina Brueckmann, João Pedro Ferreira, Piotr Ponikowski, Naveed Sattar, Gerasimos Filippatos, Sven Schnaidt, Edimar Bocchi, Michael Böhm, Jindrich Spinar, Cordula Zeller, Nadia Giannetti, Milton Packer, Anker, S, Butler, J, Filippatos, G, Ferreira, J, Bocchi, E, Böhm, M, Brunner-La Rocca, H, Choi, D, Chopra, V, Chuquiure-Valenzuela, E, Giannetti, N, Gomez-Mesa, J, Janssens, S, Januzzi, J, Gonzalez-Juanatey, J, Merkely, B, Nicholls, S, Perrone, S, Piña, I, Ponikowski, P, Senni, M, Sim, D, Spinar, J, Squire, I, Taddei, S, Tsutsui, H, Verma, S, Vinereanu, D, Zhang, J, Carson, P, Lam, C, Marx, N, Zeller, C, Sattar, N, Jamal, W, Schnaidt, S, Schnee, J, Brueckmann, M, Pocock, S, Zannad, F, Packer, M, EMPEROR-Preserved Trial, I, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), and RS: Carim - H02 Cardiomyopathy

Subjects
Adult, Male, medicine.medical_specialty, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Empagliflozin, Preserved Ejection Fraction, Placebo, chemistry.chemical_compound, All institutes and research themes of the Radboud University Medical Center, Double-Blind Method, Glucosides, Diabetes mellitus, Internal medicine, medicine, Humans, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Ejection fraction, business.industry, Hazard ratio, Stroke Volume, General Medicine, Stroke volume, medicine.disease, SPIRONOLACTONE, Hospitalization, chemistry, Cardiovascular Diseases, Heart failure, Chronic Disease, Cardiology, Spironolactone, Female, business
Abstract

Item does not contain fulltext BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In this double-blind trial, we randomly assigned 5988 patients with class II-IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. RESULTS: Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P

Published
2021

4. ORAL AB AGORA1362Cardiac Involvement in Patients With Different Rheumatic Disorders1366Gender differences in the development of cardiac complications: a multicentric prospective study in a large cohort of thalassemia major patients1646Comparison of T1-mapping, T2-weighted and contrast-enhanced cine imaging at 3.0T CMR for diagnostic oedema assessment in ST-segment elevation myocardial infarction1375Evaluation of Tissue Changes in Remote Noninfarcted Myocardium after Acute Myocardial Infarction using T1-mapping1377Right ventricular long axis strain – The prognostic value of a novel parameter in non-ischemic dilated cardiomyopathy using standard cardiac magnetic resonance imaging1389The role of the right ventricular insertion point in heart failure patients with preserved ejection fraction: Insights from a cardiovascular magnetic resonance study1398Myocardial fibrosis associates with B-type natriuretic peptide levels and outcomes more than wall stress1478Prognostic Value of Pulmonary Blood Volume by Contrast-Enhanced Magnetic Resonance Imaging in Heart Failure Outpatients – The PROVE-HF Study1370Magnetic Resonance Adenosine Perfusion Imaging as Gatekeeper of Invasive Coronary1509Influence of non-invasive hemodynamic CMR parameters on maximal exercise capacity in surgically untreated patients with Ebstein's anomaly1356Proximal aortic stiffening in Turner patients is more pronounced in the presence of a bicuspid valve. A segmental functional MRI study1503Flow pattern and vascular distensibility of the pulmonary arteries in patients after repair of tetralogy of Fallot. Insights from 4D flow CMR1516Myocardial deformation characteristics of the systemic right ventricle after atrial switch operation for transposition of the great arteries1633Three-dimensional vortex formation in patients with a Fontan circulation: evaluation with 4D flow CMR1483Mitral valve prolapse: arrhythmogenic substrates by cardiac magnetic imaging1596Increased local wall shear stress after coarctation repair is associated with descending aorta pulse wave velocity: evaluation with CMR and 4D flow1636Three-dimensional wall shear stress assessed by 4Dflow CMR in bicuspid aortic valve disease1464Cardiac Amyloidosis and Aortic Stenosis – The Convergence of Two Aging Processes1630Blood T1 variability explained in healthy volunteers: an analysis on MOLLI, ShMOLLI and SASHA1408Myocardial deformation on CMR predicts adverse outcomes in carcinoid heart disease - a new marker of risk1492Myocardial Perfusion Reserve and Global Longitudinal Strain in Early Rheumatoid Arthritis1500Exercise CMR to differentiate athlete's heart from patients with early dilated cardiomyopathy1559Real-Time, x-mri guidance to optimise left ventricular lead placement for delivery of cardiac resynchronisation therapy1560The role of Cardiac magnetic resonance imaging in patients undergoing ablation for ventricular tachycardia- Defining the substrate and visualizing the outcome1590Impact of cardiovascular magnetic resonance on clinical management and decision-making of out of hospital cardiac arrest survivors with inconclusive coronary angiogram1561Detection of coronary stenosis at rest using Oxygenation-Sensitive Magnetic Resonance Imaging

Author

J. Ranjit Arnold, A. Baritussio, S. Oebel, Jonathan Behar, G. Claessen, G.J. Fent, B. Liu, Stefania Rosmini, João L. Cavalcante, Lydia Dux-Santoy, I. Nederend, Manuel De Lazzari, Vivian P. Kamphuis, B.E.U. Burkhardt, Beate Ruecker, Daniel G.H. Devos, Christian Meierhofer, Peter Bernhardt, F. Ricci, Aatif Sayeed, Andreas A. Kammerlander, Nisha Arenja, P. Stefan Biesbroek, Sheraz A. Nazir, A. Meloni, S. Greulich, D. Kitterer, J. Latus, J. Henes, R. Kurmann, S. Gloekler, A. Wahl, S. Buss, H. Katus, M. Bobbo, M. Lombardi, N. Braun, M.D. Alscher, U. Sechtem, H. Mahrholdt, M.G. Neri, P. Preziosi, E. Grassedonio, N. Schicchi, P. Keilberg, S. Pulini, E. Facchini, V. Positano, A. Pepe, Abhishek Shetye, Jamal N. Khan, Anvesha Singh, Prathap Kanagala, Daniel Swarbrick, Gaurav Gulsin, Matthew Graham-Brown, Iain Squire, Anthony Gershlick, Gerry P. McCann, Raquel P. Amier, Paul F.A. Teunissen, Lourens F.H.J. Robbers, Aernout M. Beek, Albert C. van Rossum, Mark B.M. Hofman, Niels van Royen, Robin Nijveldt, Johannes H Riffel, Charly Noel Djiokou, Florian Andre, Thomas Fritz, Manuel Halder, Zelniker Thomas, Grigorios Korosoglou, Hugo A Katus, Sebastian J Buss, Marianne L. Schwaiger, Franz Duca, Stefan Aschauer, Beatrice A. Marzluf, Caroline Zotter-Tufaro, Daniel Dalos, Stefan Pfaffenberger, Diana Bonderman, Julia Mascherbauer, Yaron Fridman, Brianne Hackman, Ajay Kadakkal, Maren Maanja, Hussein Abu Daya, Timothy C. Wong, Erik B. Schelbert, A. Barison, G. Todiere, R. Gaeta, S. Galllina, M. Emdin, R. De Caterina, G.D. Aquaro, Dominik Buckert, Nils Dyckmanns, Wolfgang Rottbauer, Andreas Kühn, Nerejda Shehu, Jan Müller, Heiko Stern, Peter Ewert, Sohrab Fratz, Manfred Vogt, Katya De Groote, Danilo Babin, Laurent Demulier, Yves Taeymans, Jos J. Westenberg, Luc Van Bortel, Patrick Segers, Eric Achten, Jean De Schepper, Ernst Rietzschel, Julia Geiger, Malek Makki, Barbara Burkhardt, Christian J. Kellenberger, Emanuela R. Valsangiacomo Buechel, C.J. Kellenberger, J. Geiger, B. Ruecker, E.R. Valsangiacomo Buechel, Mohammed S.M. Elbaz, Lucia J.M. Kroft, Rob J. van der Geest, Albert de Roos, Nico A. Blom, Jos J.M. Westenberg, Arno A.W. Roest, Alberto Cipriani, Angela Susana, Stefania Rizzo, Benedetta Giorgi, Lacognata Carmelo, Emanuele Bertaglia, Barbara Bauce, Domenico Corrado, Gaetano Thiene, Martina Perazzolo Marra, Cristina Basso, Sabino Iliceto, A.A.W. Roest, P.J. van den Boogaard, A.D.J. ten Harkel, J.C.N. de Geus, L.J.M. Kroft, A. de Roos, J.J.M. Westenberg, Raquel Kale, Gisela Teixido-Tura, Giuliana Maldonado, Marina Huguet, David Garcia-Dorado, Artur Evangelista, Jose Rodriguez-Palomares, Shasank Rijal, John T. Schindler, Thomas G. Gleason, Joon S. Lee, Heerajnarain Bulluck, Thomas A Treibel, Anish Bhuva, Amna Abdel-Gadir, Veronica Culotta, Ahmed Merghani, Viviana Maestrini, Anna S Herrey, Peter Kellman, Charlotte Manisty, James C Moon, M.K. Hayer, S. Baig, T. Shah, S.J. Rooney, N.C. Edwards, R.P. Steeds, P. Garg, P. Swoboda, L.E. Dobson, T.A. Musa, J.F. Foley, P. Haaf, J.P. Greenwood, S. Plein, F. Schnell, J. Bogaert, S. Dymarkowski, N. Pattyn, P. Claus, J. Van Cleemput, A. La Gerche, H. Heidbuchel, Daniel Toth, Sabrina Reiml, Maria Panayiotou, Simon Claridge, Tom Jackson, Manav Sohal, Jessica Webb, Mark O'Neill, Alexander Brost, Peter Mountney, Reza Razavi, Kawal Rhode, Christopher Aldo Rinaldi, A. Arya, S. Hilbert, A. Bollmann, G. Hindricks, C. Jahnke, I. Paetsch, B. Dinov, M. Perazzolo Marra, A. Ghosh Dastidar, J. Rodrigues, A. Zorzi, A. Susana, A. Scatteia, E. De Garate, G. Mattesi, J. Strange, D. Corrado, C. Bucciarelli-Ducci, Michael Jerosch-Herold, Theodoros D. Karamitsos, Jane M. Francis, Paul Bhamra-Ariza, Rizwan Sarwar, Robin Choudhury, Joseph B. Selvanayagam, and Stefan Neubauer

Subjects
medicine.medical_specialty, business.industry, Bicuspid valve, Internal medicine, Cardiology, Medicine, Radiology, Nuclear Medicine and imaging, General Medicine, Cardiology and Cardiovascular Medicine, business, Stiffening
Published
2016

5. Risk Factors for Nonadherence to Antihypertensive Treatment

Author

Robert Holaj, Prashanth Patel, Artur Akbarov, Christobelle White, Angela Kinnell, Richard Lee Cole, Pankaj Gupta, Jiří Widimský, Branislav Štrauch, Ondřej Petrák, Paul R. Smith, Věra Marešová, John R. Thompson, Bryan Williams, Maciej Tomaszewski, Florence Lai, Ján Rosa, Gaurav S Gulsin, Iain Squire, Veena Patel, Tomáš Zelinka, and Nilesh J. Samani

Subjects
Male, medicine.medical_specialty, hypertension, 030204 cardiovascular system & hematology, Pharmacology, Risk Assessment, Severity of Illness Index, Odds, Medication Adherence, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Sex Factors, Predictive Value of Tests, Internal medicine, Severity of illness, Internal Medicine, Medicine, Humans, adherence, 030212 general & internal medicine, polypharmacy, Diuretics, Antihypertensive Agents, Aged, Czech Republic, Retrospective Studies, Polypharmacy, business.industry, Age Factors, blood pressure, Retrospective cohort study, Blood Pressure Determination, Middle Aged, diuretics, United Kingdom, Blood pressure, Predictive value of tests, Hypertension, Patient Compliance, Female, Risk assessment, business, Cohort study
Abstract

Nonadherence to antihypertensive treatment is a critical contributor to suboptimal blood pressure control. There are limited and heterogeneous data on the risk factors for nonadherence because few studies used objective-direct diagnostic methods. We used high-performance liquid chromatography-tandem mass spectrometry of urine and serum to detect nonadherence and explored its association with the main demographic- and therapy-related factors in 1348 patients with hypertension from 2 European countries. The rates of nonadherence to antihypertensive treatment were 41.6% and 31.5% in the UK and Czech populations, respectively. Nonadherence was inversely related to age and male sex. Each increase in the number of antihypertensive medications led to 85% and 77% increase in nonadherence ( P P ≤0.005 in both populations). The predictive model for nonadherence, including age, sex, diuretics, and the number of prescribed antihypertensives, showed area under the curves of 0.758 and 0.710 in the UK and Czech populations, respectively. The area under the curves for the UK model tested on the Czech data and for the Czech model tested on UK data were calculated at 0.708 and 0.756, respectively. We demonstrate that the number and class of prescribed antihypertensives are modifiable risk factors for biochemically confirmed nonadherence to blood pressure–lowering therapy. Further development of discriminatory models incorporating these parameters might prove clinically useful in assessment of nonadherence in countries where biochemical analysis is unavailable.

Published
2016

6. Evidence-based drug treatment of chronic heart failure

Author

Iain Squire

Subjects
Drug, medicine.medical_specialty, Evidence-based practice, business.industry, media_common.quotation_subject, Pharmacology (nursing), medicine.disease, Drug treatment, Heart failure, Internal medicine, medicine, Cardiology, Pharmacology (medical), Intensive care medicine, business, media_common
Abstract

A wide range of drugs to treat heart failure is available, and an evidence-based approach to management is now possible. Our Drug review discusses the properties and side-effects of the various drug groups, followed by sources of further information. Copyright © 2009 Wiley Interface Ltd

Published
2009

7. Current drug management of chronic heart failure

Author

Iain Squire

Subjects
Drug, medicine.medical_specialty, business.industry, media_common.quotation_subject, medicine.medical_treatment, Pharmacology (nursing), medicine.disease, Internal medicine, Heart failure, ACE inhibitor, medicine, Cardiology, Pharmacology (medical), Diuretic, Intensive care medicine, business, media_common, medicine.drug
Abstract

For most patients with heart failure, treatment will now include a diuretic, an ACE inhibitor or angiotensin-II inhibitor and a beta-blocker. Our Drug review discusses the properties and side-effects of the wide range of drugs available, followed by sources of further information and the Datafile. Copyright © 2006 Wiley Interface Ltd

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results